e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
COPD treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of short-acting bronchodilators (BDs) on the severity of respiratory muscle (RM) strength in COPD patients (pts)
B. Basina, T. Pertseva, L. Konopkina (Dnipropetrovsk, Ukraine)
Source:
Annual Congress 2013 –COPD treatment
Session:
COPD treatment
Session type:
Thematic Poster Session
Number:
3679
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Basina, T. Pertseva, L. Konopkina (Dnipropetrovsk, Ukraine). Effect of short-acting bronchodilators (BDs) on the severity of respiratory muscle (RM) strength in COPD patients (pts). Eur Respir J 2013; 42: Suppl. 57, 3679
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Additional therapy of COPD patients with respiratory muscles dysfunction
Source: International Congress 2014 – Comorbidities
Year: 2014
Effects of routine inspiratory muscle training (IMT) as add-on to pulmonary rehabilitation (PR) in COPD
Source: International Congress 2015 – Latest insights into pulmonary rehabilitation
Year: 2015
Use of intravenous (IV) aminophylline in acute exacerbations of COPD with decompensated acidotic type 2 respiratory failure (T2RF) requiring non-invasive ventilation (NIV)
Source: Annual Congress 2013 –Clinical trials of LAMAs, LABAs, MABAs and theophylline for asthma and COPD
Year: 2013
Glycopyrronium (GLY) and tiotropium (TIO) comparison: Lung function, dyspnea and health status in COPD patients in all GOLD groups
Source: International Congress 2015 – New data on established treatments for asthma and COPD
Year: 2015
Reproducibility and reliability of parasternal electromyography in patients with COPD and obesity related respiratory failure (ORRF)
Source: Annual Congress 2013 –Respiratory muscles at rest and during exercise: from physiology to clinical context
Year: 2013
Umeclidinium/vilanterol (UMEC/VI) once daily (OD) vs fluticasone/salmeterol combination (FSC) twice daily (BD) in patients with moderate-to-severe COPD and infrequent COPD exacerbations
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
The estimation of respiratory muscles (RM) status by echodensitometry in male patients with acute exacerbation of COPD (AECOPD)
Source: Annual Congress 2010 - Interaction between respiratory and peripheral muscles
Year: 2010
Efficacy and tolerability of budesonide/formoterol (B/F) added to tiotropium (T) vs T alone in East-Asian patients (pts) with severe/very severe chronic obstructive pulmonary disease (COPD)
Source: International Congress 2014 – Clinical trials of drugs and biomarkers for respiratory diseases
Year: 2014
Impulse-oscillometry (IOS) differences in asthma and COPD patients, and healthy-subjects
Source: International Congress 2014 – Airways: reversibility and responsiveness
Year: 2014
Neural respiratory drive (NRD) measured by parasternal electromyography predicts clinical deterioration and early readmission in patients with acute exacerbation of COPD (AECOPD)
Source: International Congress 2014 – Respiratory pathophysiology: mechanisms of alteration of lung, respiratory and peripheral muscle function
Year: 2014
Surfactant protein D (SPD) like marker of effectiveness in patients (pts) with acute exacerbations (AE) of COPD ofphosphatidylcholine treatment outcomes
Source: International Congress 2015 – Different data in COPD
Year: 2015
Response to the combined therapy in COPD patients (pts) with different plasma surfactant protein D (SPD) level
Source: International Congress 2014 – COPD markers
Year: 2014
Treatment effect of inhaled prolonged bronchodilator therapy (IPBT) combined with inhaled glucocorticosteroids (IGCS) on respiratory symptoms and external respiratory function in MDR pulmonary TB patients with broncho-obstructive syndrome (BOS)
Source: Annual Congress 2012 - New insights in the clinical management of lung diseases
Year: 2012
Erdosteine improves airflow in patients with severe exacerbation of COPD (AECOPD)
Source: International Congress 2016 – Novel avenues in the treatment of COPD II
Year: 2016
Dynamic changes in quadriceps strength and 6 minute walk distance during COPD exacerbations in the COPDMAP consortium
Source: International Congress 2014 – Comorbidities
Year: 2014
Correlations between respiratory muscle strength, functional and non-functional parameters in COPD patients
Source: International Congress 2014 – Innovative technology and techniques in respiratory function
Year: 2014
Comparison of inspiratory flow rates using an innovative dry powder inhaler (DPI) in patients with mild–severe asthma and severe COPD
Source: International Congress 2014 – Rationale behind respiratory drug development
Year: 2014
Comparison of the acute effects of formoterol (F) and formoterol/budesonide combination (FBC) on blood-gas tensions in patients with acute exacerbation of COPD (AECOPD)
Source: Annual Congress 2003 - Progress on therapy for chronic obstructive pulmonary disease
Year: 2003
Effect of inhaled vilanterol trifenatate/fluticasone furoate on breathing pattern, dyspnea and respiratory muscle function in severe COPD
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014
The relationship between proximal limb and trunk muscle strength and respiratory parameters in chronic obstructive pulmonary disease (COPD)
Source: International Congress 2015 – Functional capacity, exercise and pulmonary rehabilitation in chronic lung diseases
Year: 2015
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept